Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

Repligen

6 Disclosed Funding Rounds $918,225,000

0 Participating Investments


Pharmaceutical, Consumer Goods, Biotechnology, Manufacturing

Repligen is a biopharmaceutical company developing consumable products for the manufacture of biological drugs.

Waltham, Massachusetts, United States, North America (US)

Organizations in Waltham in Pharmaceutical,
Organizations in Waltham in Consumer Goods,
Organizations in Waltham in Biotechnology,
Organizations in Waltham in Manufacturing,
Organizations in Massachusetts in Pharmaceutical,
Organizations in Massachusetts in Consumer Goods,
Organizations in Massachusetts in Biotechnology,
Organizations in Massachusetts in Manufacturing,
Organizations in United States in Pharmaceutical,
Organizations in United States in Consumer Goods,
Organizations in United States in Biotechnology,
Organizations in United States in Manufacturing,
Organizations in North America in Pharmaceutical,
Organizations in North America in Consumer Goods,
Organizations in North America in Biotechnology,
Organizations in North America in Manufacturing

Investors in Waltham in Pharmaceutical,
Investors in Waltham in Consumer Goods,
Investors in Waltham in Biotechnology,
Investors in Waltham in Manufacturing,
Investors in Massachusetts in Pharmaceutical,
Investors in Massachusetts in Consumer Goods,
Investors in Massachusetts in Biotechnology,
Investors in Massachusetts in Manufacturing,
Investors in United States in Pharmaceutical,
Investors in United States in Consumer Goods,
Investors in United States in Biotechnology,
Investors in United States in Manufacturing,
Investors in North America in Pharmaceutical,
Investors in North America in Consumer Goods,
Investors in North America in Biotechnology,
Investors in North America in Manufacturing

Greater Boston Area (0 Investors) (0 Startups), New England (0 Investors) (0 Startups), East Coast (0 Investors) (0 Startups), Northeastern US (0 Investors) (0 Startups)

Founded date 01, 1981

Founders Paul Schimmel

Operating Status Active

Funding Stage IPO

Last Funding Type Post-IPO Equity

Company Type For Profit


Twitter Link

LinkedIN Link

Wikipedia Link

Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A resins that are used to separate and purify monoclonal antibody therapeutics. Our ATF (Alternating Tangential Flow) systems and our growth factor products are used to increase product yield during the fermentation stage of biologic drug manufacturing. In addition, we developed and market an innovative line of “ready-to-use” chromatography columns under our OPUS® and MediaScout® brands that we deliver pre-packed with our customers’ choice of resin. Repligen’s corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Lund, Sweden and Weingarten, Germany.

Date Round Raised Lead
December, 07, 2020 Post-IPO Equity $312,225,000 -------
July, 19, 2019 Post-IPO Equity $138,100,000 -------
July, 19, 2019 Convertible Note $287,500,000 -------
April, 30, 2019 Post-IPO Equity $175,000,000 -------
June, 18, 2014 Venture - Series Unknown $4,000,000 -------
December, 15, 2010 Grant $1,400,000 -------